Emerging Growth Research Reports Continued Revenue Growth at Immuron
ACCESSWIRE•04/11/2026•18:10 ET
1
Key Highlights
- ➤1Q FY2027 global product revenue rose 9% year-over-year to AUD $2.2 million
- ➤Australia revenue increased 14%, supported by Travelan® relaunch and PROIBS® penetration
- ➤U.S. revenue declined 19%; Canadian revenue surged 286% year-over-year
- ➤FY2026 net loss improved to AUD $3.8 million, down $1.4 million year-over-year
- ➤EGR reiterated Buy-Extended and updated Immuron’s 12-month price target
NEW YORK CITY, NY / ACCESS Newswire / November 4, 2026 / Emerging Growth Research ("Emerging Growth Research" or "EGR") today announced the release of its company-sponsored research Flash Report on Immuron Limited (NASDAQ:IMRN), reiterating its Buy-Extended rating and updating its 12-month price target.
The Flash Report reviews Immuron's first-quarter FY2027 results, which showed continued year-over-year revenue growth, and discusses the Company's commercial products, clinical development pipeline, and strategic partnering plans.
Get started
Create a free account to read the full story.